Journal of Peking University(Health Sciences) >
Received date: 2022-11-26
Online published: 2024-10-16
Supported by
the Clinical Cohort Construction Program of Peking University Third Hospital and the Key Clinical Projects of Peking University Third Hospital(BYSY2017026)
Copyright
仁珍 管 , 士刚 丁 , 岩岩 石 , 艳 薛 . [J]. Journal of Peking University(Health Sciences), 2024 , 56(5) : 942 -945 . DOI: 10.19723/j.issn.1671-167X.2024.05.031
| 1 | 吕秋菊, 蒲强红. CYP2C19基因多态性对含左氧氟沙星方案根除幽门螺杆菌疗效影响的Meta分析[J]. 中国医药导刊, 2017, 19 (11): 1174- 1180. |
| 2 | 刘文忠, 谢勇, 陆红, 等. 第五次全国幽门螺杆菌感染处理共识报告[J]. 中华消化杂志, 2017, 37 (6): 364- 378. |
| 3 | Nagy P , Johansson S , Molloy-Bland M . Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA[J]. Gut Pathog, 2016, 8, 8. |
| 4 | Cai Q , Zhu C , Yuan Y , et al. Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: A nationwide multicentre study[J]. Gut, 2019, 68 (9): 1576- 1587. |
| 5 | Bakhti SZ , Latifi-Navid S , Zahri S . Unique constellations of five polymorphic sites of Helicobacter pylori vacA and cagA status associated with risk of gastric cancer[J]. Infect Genet Evol, 2020, 79, 104167. |
| 6 | Bartpho TS , Wattanawongdon W , Tongtawee T , et al. Precan-cerous gastric lesions with Helicobacter pylori vacA+/babA2+/oipA+ genotype increase the risk of gastric cancer[J]. Biomed Res Int, 2020, 2020, 7243029. |
| 7 | Sugano K , Tack J , Kuipers EJ , et al. Kyoto global consensus report on Helicobacter pylori gastritis[J]. Gut, 2015, 64 (9): 1353- 1367. |
| 8 | Graham DY , Lu H , Yamaoka Y . A report card to grade Helicobacter pylori therapy[J]. Helicobacter, 2007, 12 (4): 275- 278. |
| 9 | 张建中. 中国幽门螺杆菌治疗低根除率现状及应对策略[J]. 胃肠病学和肝病学杂志, 2017, 26 (6): 637- 639. |
| 10 | 李一凡, 胡庆林, 费繁荣, 等. 深圳市17 589例体检人群中幽门螺杆菌分型结果分析[J]. 国际检验医学杂志, 2021, 42 (16): 1921- 1924. |
| 11 | Mamori S , Higashida A , Kawara F , et al. Age-dependent eradication of Helicobacter pylori in Japanese patients[J]. World J Gastroenterol, 2010, 16 (33): 4176- 4179. |
| 12 | Meyer JM , Silliman NP , Wang W , et al. Risk factors for Helicobacter pylori resistance in the United States: The surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999[J]. Ann Intern Med, 2002, 136 (1): 13- 24. |
| 13 | Liang X , Xu X , Zheng Q , et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study[J]. Clin Gastroenterol Hepatol, 2013, 11 (7): 802- 807. |
| 14 | Chen Q , Zhang W , Fu Q , et al. Rescue therapy for Helicobacter pylori eradication: A randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy[J]. Am J Gastroenterol, 2016, 111 (12): 1736- 1742. |
| 15 | Bai P , Zhou LY , Xiao XM , et al. Susceptibility of Helicobacter pylori to antibiotics in Chinese patients[J]. J Dig Dis, 2015, 16 (8): 464- 470. |
| 16 | Zhang YX , Zhou LY , Song ZQ , et al. Primary antibiotic resis-tance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: A prospective serial study[J]. World J Gastroenterol, 2015, 21 (9): 2786- 2792. |
/
| 〈 |
|
〉 |